TYK2 heats up with Ven­tyx eye­ing mid-stage tri­als; Nex­Im­mune cites com­pe­ti­tion in pipeline cull

Ven­tyx said it will be­gin test­ing its TYK2 in­hibitor in mul­ti­ple mid-stage clin­i­cal tri­als be­fore the clock strikes 2023.

The news comes just weeks be­fore Bris­tol My­ers Squibb is slat­ed to find out whether it will be the first to se­cure a TYK2 drug ap­proval, for its mod­er­ate to se­vere pso­ri­a­sis as­set deu­cravac­i­tinib.

With pos­i­tive re­sults from a healthy vol­un­teer study, the Cal­i­for­nia biotech will soon test VTX958 in pa­tients with pso­ri­a­sis, Crohn’s dis­ease and pso­ri­at­ic arthri­tis. Ul­cer­a­tive col­i­tis and lu­pus could al­so be ex­plored.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER